BR9601478A - Utilizações de ao menos um antagonista de CGRP composição cosmética farmacêutica e/ou dermatológica processo de tratamento cosmético de vermilhidões cutâneas e processo de tratamento cosmético de rosásea e/ou de eritema pudico - Google Patents

Utilizações de ao menos um antagonista de CGRP composição cosmética farmacêutica e/ou dermatológica processo de tratamento cosmético de vermilhidões cutâneas e processo de tratamento cosmético de rosásea e/ou de eritema pudico

Info

Publication number
BR9601478A
BR9601478A BR9601478A BR9601478A BR9601478A BR 9601478 A BR9601478 A BR 9601478A BR 9601478 A BR9601478 A BR 9601478A BR 9601478 A BR9601478 A BR 9601478A BR 9601478 A BR9601478 A BR 9601478A
Authority
BR
Brazil
Prior art keywords
cosmetic composition
cgrp antagonist
antagonist pharmaceutical
dermatological cosmetic
dermatological
Prior art date
Application number
BR9601478A
Other languages
English (en)
Inventor
Lacharriere Olivier De
Breton Lionel
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9601478(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of BR9601478A publication Critical patent/BR9601478A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR9601478A 1995-03-28 1996-03-27 Utilizações de ao menos um antagonista de CGRP composição cosmética farmacêutica e/ou dermatológica processo de tratamento cosmético de vermilhidões cutâneas e processo de tratamento cosmético de rosásea e/ou de eritema pudico BR9601478A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (1)

Publication Number Publication Date
BR9601478A true BR9601478A (pt) 1998-06-02

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9601478A BR9601478A (pt) 1995-03-28 1996-03-27 Utilizações de ao menos um antagonista de CGRP composição cosmética farmacêutica e/ou dermatológica processo de tratamento cosmético de vermilhidões cutâneas e processo de tratamento cosmético de rosásea e/ou de eritema pudico

Country Status (15)

Country Link
US (2) US5932215A (pt)
EP (1) EP0734729B2 (pt)
JP (1) JPH08268874A (pt)
AR (1) AR002974A1 (pt)
AT (1) ATE168011T1 (pt)
BR (1) BR9601478A (pt)
CA (1) CA2172777C (pt)
DE (1) DE69600399T3 (pt)
DK (1) DK0734729T4 (pt)
ES (1) ES2121461T5 (pt)
FR (1) FR2732221B1 (pt)
HU (1) HUP9600765A3 (pt)
MX (1) MX9601150A (pt)
PL (1) PL313515A1 (pt)
RU (1) RU2152798C1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
EP1385496A4 (en) * 2001-05-09 2006-03-29 Univ Michigan USE OF COMPOSITIONS FOR THE TREATMENT OF ROSACEA
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
MXPA05001649A (es) 2002-08-12 2005-05-27 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PT2380592T (pt) 2005-11-14 2018-06-06 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
CA2727710C (en) * 2008-06-11 2016-11-01 Biochemics, Inc. Control of blood vessel physiology to treat skin disorders
AU2009291755B2 (en) 2008-09-10 2016-04-21 Biochemics, Inc. Ibuprofen for topical administration
US9566256B2 (en) 2008-09-22 2017-02-14 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
BRPI0921959A2 (pt) 2008-12-04 2017-05-30 Biochemics Inc métodos e composições para remoção de tatuagem
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
CN102985091B (zh) * 2010-03-03 2016-11-23 新科蒂斯公司 使用抗微生物肽螯合化合物治疗皮肤疾病和异常的组合物和方法
WO2011117377A2 (en) 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
CN108359008B (zh) 2011-05-20 2022-03-29 H.伦德贝克公司 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
ES2873837T3 (es) 2011-05-20 2021-11-04 H Lundbeck As Composiciones anti CGRP y uso de las mismas
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
FR3030521B1 (fr) 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (pt) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
NZ283135A (en) * 1994-03-21 2004-12-24 Thomsen John Brown Gel formulation for treatment of skin diseases and disinfection/disinfestation of the skin
ATE228834T1 (de) * 1994-09-30 2002-12-15 Oreal Verwendung von einem agonisten eines mit einem chloridkanal assozierten rezeptors zur behandlung von hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
HU9600765D0 (en) 1996-05-28
EP0734729B1 (fr) 1998-07-08
DK0734729T3 (da) 1999-04-19
CA2172777A1 (fr) 1996-09-29
MX9601150A (es) 1997-02-28
US5932215A (en) 1999-08-03
EP0734729A1 (fr) 1996-10-02
PL313515A1 (en) 1996-09-30
ATE168011T1 (de) 1998-07-15
EP0734729B2 (fr) 2004-09-29
AR002974A1 (es) 1998-05-27
FR2732221B1 (fr) 1997-04-25
DE69600399T3 (de) 2005-07-14
HUP9600765A3 (en) 1998-04-28
CA2172777C (fr) 2007-07-24
ES2121461T5 (es) 2005-05-01
ES2121461T3 (es) 1998-11-16
DK0734729T4 (da) 2004-10-25
HUP9600765A2 (en) 1997-06-30
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
FR2732221A1 (fr) 1996-10-04
JPH08268874A (ja) 1996-10-15
DE69600399D1 (de) 1998-08-13
DE69600399T2 (de) 1998-10-29

Similar Documents

Publication Publication Date Title
BR9601478A (pt) Utilizações de ao menos um antagonista de CGRP composição cosmética farmacêutica e/ou dermatológica processo de tratamento cosmético de vermilhidões cutâneas e processo de tratamento cosmético de rosásea e/ou de eritema pudico
PL312481A1 (en) Application of cgrp antagonist in cosmetic, pharmaceutical or dermatological composition and so obtained composition as such
BR9610375A (pt) Extrato de células composição cosmética ou farmacêutica utilização de pelo menos um extrato de células e processo de tratamento cosmético
BR9800660A (pt) Emulsão água-em-óleo sua utilização composição cosmética e/ou dermatológica processo de tratamento cosmético e utilzação de uma associação
BR9609831A (pt) Composições cosméticas e/ou farmacêuticas antipruríticas
BR9802120A (pt) Composição cosmética e/ou dermatológica composição dermatologica processo de tratamento cosmético utilização de uma composição processo de conservação de composições e utilização de um polímero poliaminado
BR9608500A (pt) Utilização de pelo menos um extrato de pelo menos uma bactéria filamentosa não fotossintética composição cosmética ou farmacêutica e processo de tratamento cosméstico
BR9604632A (pt) Compostos bicíclicos aromáticos utilizaçao de pelo menos um dos compostos composiçao farmacêutica composiçao cosmética e utilizaçao de uma composiçao cosmética
BR9604031A (pt) Uso de pelo menos um composto escolhido de antagonistas de bradiquinina uso em uma composição tópica de pelo menos um composto escolhido de antagonistas de bradiquinha processo de tratamento cosmético e composição cosmética farmacêutica ou dermatológica
BR9608376A (pt) Utilização em cosméticos de uma composição sólida expandida composição de uso cosmético ou dermatológico processo de preparação de uma composição e utilização de composição
ID17407A (id) Formulasi kosmetik dan/atau farmasi
DE59607535D1 (de) Kosmetische und/oder pharmazeutische zubereitungen
BR9604631A (pt) Compostos bicíclicos aromáticos utilizaçao de compostos composiçao farmacêutica composiçao cosmética e sua utilizaçao
BR9611302A (pt) Utilização de pelo menos um agonista beta-adrenérgico processo de tratamento cosmético e composição cosmética ou farmacêutica
FR2760362B1 (fr) Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
BR9601467A (pt) Utilização de ao menso um antagonista de cgrp composição cosmética farmacêutica e/ou dermatológica e processo de tratamento cosmético
BR9702882A (pt) Utilização de derivados de 3-óxido de pirimidina composição cosmética ou farmacêutica e produto
BR9610530A (pt) Derivados de acriloilguanidina substituíduo com heteroarila e composiç es farmacêuticas contendo os mesmos
BR9505381A (pt) Utilização de ao menos um antagonista de substáncia p e utilização de um antagonista de substáncia p
BR9601461A (pt) Utilizações de ao menos um antagonista de cgrp composição cosmética e/ou farmacêutica para olhos sensíveis e processo de tratamento ou maquiagem de olhos sensíveis
BR9800753B1 (pt) composição cosmética e/ou dermatológica e uso de uma composição.
DE59610263D1 (de) Kosmetische und/oder pharmazeutische Emulsionen
MC2394A1 (fr) Composition destinée à stopper la chute et/ou à favoriser
DE59607760D1 (de) Kosmetische und/oder pharmazeutische Emulsionen
FR2724318B1 (fr) Composition cosmetique prevenant ou attenuant la photo-reactivite de manopigments de dioxyde de titane

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O E 13 DALPI 9279/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: ANULADA A PUBLICACAO POR TER SIDO INDEVIDA REF : RPI 1935 DE 06/02/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24 E ART. 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/395 (2006.01), A61K 38/22 (2006.0